Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 17, 2026 13:55 ET | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma, Ltd., (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors...
February 17, 2026 09:41 ET | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma Ltd. (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that...
February 10, 2026 09:00 ET | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

LOS ANGELES, Feb. 10, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma Ltd. (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that...
February 02, 2026 10:46 ET | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors

LOS ANGELES, Feb. 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma Ltd. (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that...
January 26, 2026 09:26 ET | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors

LOS ANGELES, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma Ltd. (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that...
December 23, 2025 08:00 ET | Source: Quantum BioPharma

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company...
November 07, 2025 07:00 ET | Source: Quantum BioPharma

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern’ Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce its financial and operational...
October 20, 2025 08:30 ET | Source: Quantum BioPharma

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company...
August 07, 2025 07:00 ET | Source: Quantum BioPharma

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce its financial and operational...
July 22, 2025 07:00 ET | Source: Quantum BioPharma

Quantum BioPharma Makes Strategic Investment in GameStop Corp.

TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company...